These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8595507)

  • 21. Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report.
    Capiluppi B; Saracco A; Gianotti N; Mussini C; Butini L; Tomasoni L; De Gennaro M; Rizzolo L; Monolo G; Cargnel A; Moioli C; Arici C; Portelli V; Rizzardini G; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):73-8. PubMed ID: 12003179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 drug resistance assays in clinical management.
    Martinez-Picado J; D'Aquila R
    AIDS Clin Care; 1998 Nov; 10(11):81-5, 87-8. PubMed ID: 11365861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of drug resistance on viral load in patients failing antiretroviral therapy.
    Machouf N; Thomas R; Nguyen VK; Trottier B; Boulassel MR; Wainberg MA; Routy JP
    J Med Virol; 2006 May; 78(5):608-13. PubMed ID: 16555280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
    Montroni M; Monforte AD
    Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral resistance: how it may affect treatment options.
    Biehler GV
    Body Posit; 1998 Jun; 11(6):42-3. PubMed ID: 11365610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
    Rusconi S; De Pasquale MP; Milazzo L; Moscatelli G; Bulgheroni E; Citterio P; d'Arminio-Monforte A; Moroni M; Galli M
    Antivir Ther; 1997 Jan; 2(1):39-46. PubMed ID: 11322265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV pathogenesis and treatment strategies.
    Vella S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S20-3. PubMed ID: 8595503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
    Narciso P; Lazzarin A
    Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will drug resistance testing prove reliable enough to enhance HIV treatments?
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(6):1-3. PubMed ID: 11366139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
    Torti C; Quiros-Roldan E; Regazzi M; De Luca A; Mazzotta F; Antinori A; Ladisa N; Micheli V; Orani A; Patroni A; Villani P; Lo Caputo S; Moretti F; Di Giambenedetto S; Castelnuovo F; Maggi P; Tinelli C; Carosi G;
    Clin Infect Dis; 2005 Jun; 40(12):1828-36. PubMed ID: 15909273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 burden as a marker of disease progression and clinical response to therapy in AIDS.
    Coombs RW
    Clin Lab Med; 1994 Jun; 14(2):301-11. PubMed ID: 7924193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.
    Schooley RT
    AIDS; 1995 Dec; 9 Suppl 2():S15-S19. PubMed ID: 8775802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An approach to antiretroviral treatment of HIV disease. Individualized therapy: the role of viral-burden measures.
    Thompson MA
    Hosp Pract (1995); 1995 Aug; 30 Suppl 1():41-50. PubMed ID: 7635916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An approach to antiretroviral treatment of HIV disease. Combined antiretroviral therapy: the emerging role.
    Deeks S; Volberding P
    Hosp Pract (1995); 1995 Aug; 30 Suppl 1():23-31. PubMed ID: 7635914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current clinical aspects of AIDS].
    Clumeck N
    Bull Mem Acad R Med Belg; 1993; 148(5-6):234-9; discussion 240-1. PubMed ID: 8142932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four new concepts for combatting HIV infection...and why they won't be tried anytime soon.
    PI Perspect; 1995 Dec; (no 17):1-3, 13-4. PubMed ID: 11363102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virologic parameters as surrogate markers for clinical outcome in HIV-1 disease: verification, variation, and validation.
    Reichelderfer PS; Coombs RW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S19-24. PubMed ID: 7552509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancouver: optimism, but at a cost.
    Churchill D; Pym A; Coker R
    Int J STD AIDS; 1996 Oct; 7(6):385-7. PubMed ID: 8940665
    [No Abstract]   [Full Text] [Related]  

  • 39. Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.
    Ciborowski P
    Biomark Med; 2009 Dec; 3(6):771-85. PubMed ID: 20477714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons.
    Brambilla D; Leung S; Lew J; Todd J; Herman S; Cronin M; Shapiro DE; Bremer J; Hanson C; Hillyer GV; McSherry GD; Sperling RS; Coombs RW; Reichelderfer PS
    J Clin Microbiol; 1998 Jan; 36(1):311-4. PubMed ID: 9431977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.